Premium
Free‐to‐total prostate‐specific antigen ratios 18–24 months following external beam radiation for adenocarcinoma of the prostate
Author(s) -
Ward John F.,
Johnstone Peter A.S.,
Kane Christopher J.
Publication year - 1999
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199902)70:2<91::aid-jso5>3.0.co;2-n
Subject(s) - medicine , external beam radiation , radiation therapy , prostate , prostate specific antigen , external beam radiotherapy , urology , prostate cancer , nuclear medicine , oncology , cancer , brachytherapy
Abstract Background and Objectives The purpose of this study was to evaluate free‐to‐total prostate‐specific antigen (PSA) ratios after definitive external beam radiation therapy for men with adenocarcinoma of the prostate (CaP). Methods A prospective evaluation of percent free PSA in men following definitive external beam radiation therapy for CaP was compared to men with untreated CaP and men at very low risk for CaP. Statistical comparison of clinical and pathologic parameters was performed. Results There was no statistically significant difference in free‐to‐total PSA ratios for men with newly diagnosed CaP and men with detectable PSA who were treated with external beam radiation therapy. Conclusions Free‐to‐total PSA ratios after definitive external beam radiation therapy for CaP are consistent with percent free PSA in patients with newly diagnosed CaP. This supports the theory that PSA from in situ prostate tissue following external beam radiation therapy is produced by malignant cells. J. Surg. Oncol. 1999;70:91–94. Published 1999 Wiley‐Liss, Inc.